# Fresenius Raises 2026 Outlook After Strong Third Quarter

The healthcare group reported 5% organic revenue growth and lifted its expected earnings-per-share range after gains at Kabi and Helios.

By Will Langan | 24X7 News
Published: 2026-11-04T09:05:41.599Z
Updated: 2026-11-04T09:05:41.599Z
Section: Business
Format: News
Canonical: https://24x7news.us/articles/fresenius-third-quarter-outlook-november-4-2026

Fresenius raised its 2026 expectations Wednesday after stronger third-quarter results at its Kabi pharmaceutical-products division and Helios hospital business.

The German healthcare group reported quarterly revenue of 5.80 billion euros, representing 5% organic growth. Group earnings before interest and taxes increased 10% at constant exchange rates to 638 million euros.

Core earnings per share rose 14% at constant exchange rates to 72 euro cents. Fresenius now expects full-year core earnings-per-share growth in the upper half of its 10% to 15% range. The company had previously described the broader range without specifying the upper half.

Management also raised its expected full-year group operating margin to more than 11.5%, compared with a previous indication of about 11.5%.

Fresenius Kabi, which sells injectable medicines, clinical nutrition products and medical technology, produced 391 million euros in quarterly operating earnings. The result was slightly above the 388 million-euro analyst consensus cited in the reporting.

The Helios hospital division also contributed to the quarter’s improvement. Fresenius said both major operating businesses produced organic revenue growth while cost controls and lower interest expense supported profitability.

The company’s net debt-to-earnings ratio stood at 2.5 times. Fresenius has been reducing debt and simplifying its structure under Chief Executive Michael Sen while increasing investment in selected growth areas, including biopharmaceuticals.

The upgraded outlook was Fresenius’ second guidance increase of the year. Its results contrasted with continued pressure at Fresenius Medical Care, the dialysis company in which Fresenius retains a minority stake.

Quarterly comparisons and company-adjusted measures can differ from reported accounting results. The new guidance remains subject to currency movements, hospital demand, product performance and execution of the company’s turnaround plans.

Sources:
- Fresenius third-quarter results: https://www.fresenius.com/financial-results
- Reuters: https://www.reuters.com/business/healthcare-pharmaceuticals/fresenius-raises-2026-outlook-second-time-after-strong-q3-2026-11-04/

## Sources
- Fresenius third-quarter results: https://www.fresenius.com/financial-results
- Reuters: https://www.reuters.com/business/healthcare-pharmaceuticals/fresenius-raises-2026-outlook-second-time-after-strong-q3-2026-11-04/